**Name of journal:** **World Journal of Gastroenterology**

**ESPS Manuscript NO: 5370**

**Columns: REVIEW**

**Gender specific medicine in liver diseases: a point of view**

Durazzo M *et al*. Liver in gender medicine

Marilena Durazzo, Paola Belci, Alessandro Collo, Vanessa Prandi, Erika Pistone, Maria Martorana, Roberto Gambino, Simona Bo

**Marilena Durazzo, Paola Belci, Alessandro Collo, Vanessa Prandi, Erika Pistone, Maria Martorana, Roberto Gambino, Simona Bo,** Department of Medical Sciences, University of Turin, 10126 Turin, Italy

**Author contributions:** Durazzo M participated in the conception and design of the review, manuscript writing and revision; Belci P, Collo A, Prandi V, Pistone E, Martorana M, Gambino R and Bo S participated manuscript writing. All authors read and approved the final manuscript.

**Correspondence to: Marilena Durazzo,** **Professor**, Department of Medical Science, University of Turin, Corso A.M. Dogliotti 14, 10126 Turin, Italy. marilena.durazzo@unito.it

**Telephone:** +39-11-6336040  **Fax:** +39-11-6335401

**Received:** September 2, 2013 **Revised:** November 1, 2013

**Accepted:** December 5, 2013

**Published online:**

**Abstract**

Gender medicine focuses on the patho-physiological, clinical, prevention and treatment differences in diseases that are equally represented in men and women. The purpose of gender medicine is to ensure that each individual man and woman receives the best treatment possiblebased on scientific evidence**.** The concept of “gender” includes not only the sexual characteristics of individuals but also physiological and psychological attributes of men and women, including risk factors, protective/aggravating effects of sexual hormones and variances linked to genetics and corporal structures that explain biological and physiological differences between men and women. It is very important to consider all the biological, physiological, functional, psychological, social and cultural characteristics to provide patients with individualized disease management.Herein, we critically analyze the literature regarding gender differences for diseases and acquired conditions of the most representative hepatic pathologies: primary biliary cirrhosis, autoimmune hepatitis, primary sclerosing cholangitis, non alcoholic fatty liver disease and alcoholic liver disease, and viral chronic hepatitis B and C. The last section addresses hemochromatosis, which is a prevalent iron overload disorder in the Caucasian population.This review aims to describe data from the literature concerning viral chronic hepatitis during pregnancy, management during pregnancy and delivery, and new effective drugs for the prevention of maternal infection transmission without significant adverse effects or complications.

© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words**: gender; liver disease; primary biliary cirrhosis; autoimmune hepatitis; viral chronic hepatitis B; viral chronic hepatitis C; non alcoholic fatty liver disease; alcoholic liver disease

**Core tip:** Gender medicine focuses on the patho-physiological, clinical, prevention and treatment differences in diseases that are equally represented in men and women. The concept of “gender” includes not only the sexual characteristics of individuals but also physiological and psychological attributes of men and women. In this review, we critically analyze the literature regarding gender differences for diseases and acquired conditions of the most representative hepatic pathologies: primary biliary cirrhosis, autoimmune hepatitis, primary sclerosing cholangitis, non alcoholic fatty liver disease and alcoholic liver disease, viral chronic hepatitis B and C, and hemochromatosis (the prevalent iron overload disorder in the Caucasian population).

Durazzo M, Belci P, Collo A, Prandi V, Pistone E, Martorana M, Bo S. Gender specific medicine in liver diseases: a point of view. *World J Gastroenterol* 2013;

**Available from:**

**DOI:**

**Introduction**

Gender medicine is a new aspect of medicine that focuses on to investigating the differences in diseases based on anatomic and physiological stages, from biological, functional, psychological, social and cultural points of view and analyzes the range of responses to pharmacological care. This field emerged because epidemiological and clinical surveys performed over the last 30 years have generally reported results for only gender[1].

The concept of “gender” refers not only to the sexual characteristics of individuals, but also to a set of differences derived from the physiology and psychology of men and women and from various social and cultural environments. From biological and physiological points of view, the differences between men and women may be explained by differences in the presence of risk factors, protective/aggravating effects of sexual hormones, variances linked to genetics and various corporal structures[2].

The aim of this review is to examine the available data in the literature concerning the differences between men and women for the most representative hepatic pathologies, including primary biliary cirrhosis (PBC), autoimmune hepatitis (AIH), viral chronic hepatitis B and C, non alcoholic fatty liver disease (NAFLD) and alcoholic liver disease. There are morphological differences in the liver between genders. Thus, hepatic damage may produce different consequences in men and women in ongoing primitive diseases and during acquired conditions[2].

**Autoimmune liver diseases: primary biliary cirrhosis, autoimmune hepatitis and primary sclerosing cholangitis**

Previous studies have examined gender differences in the immune system, and suggest that estrogen and androgen may modulate the immune system. Women have a significantly higher number of CD4+ T lymphocytes and a higher CD4+/CD8+ ratio than men[3].

Additionally, the secretion of interferon- (IFN-) and interleukin (IL)-10 was enhanced after the addition of estrogen in T-cell clones isolated from women[4]. Conversely, androgen inhibited, the secretions of IFN-, IL-4, and IL-5 in murine T cells[5].

These findings suggest that gender differences could have a role in autoimmune diseases.

The best example demonstrating gender differences is PBC.

PBC is a chronic cholestatic liver disease characterized by immune-mediated inflammatory destruction of the small intrahepatic bile ducts, and fibrosis. PBC can progress to cirrhosis and subsequent liver failure[6-8]. PBC is a typical female disease that occurs from 40-60 years of age[9]. The incidence rates in women and men range from 3:1 to 22:1, with an average incidence rate in women of 10:1[10]. The age at PBC diagnosis was found to be older in men (62 years) than in women (51 years)[11].

Numerous hypotheses have been formulated to justify this sex imbalance. For example, the effects of sex hormones in lymphocyte maturation/activation and the synthesis of antibodies and cytokines have been suggested as contributing factors. Additionally, the immune-modulatory effects of estrogens during reproductive life, fetal microchimerism, skewing of the X-chromosome inactivation pattern and defects in sex chromosomes have also been suggested as factors[12]. Several studies have identified an increased incidence of X haploinsufficiency in female patients[13-14].

A study bySelmi *et al*[15] indicates that epigenetic factors, such as X chromosome inactivation, may also be involved in the development of PBC, and variable concordance rates of PBC have been identified between twins. A recent study by Lleo *et al*[16] demonstrated how Y chromosome loss is associated with PBC in male patients. These epigenetic changes may be ideal targets for new personalized treatments, as suggested by cancer data. However, no convincing evidence has yet supported any of these hypotheses.Males are less likely to be symptomatic than females. Females experience pruritus as a single symptom more often than males. It has been suggested that female sex hormones may be linked with pruritus. In addition, female sex hormones may cause more abdominal pain/discomfort and constitutional symptoms (malaise, anorexia, weight loss, fatigue). In contrast, males experience more jaundice, jaundice with pruritus, and upper gastrointestinal bleeding[17].

The rates of severe daytime somnolence and depressive symptoms were found to be similar in males and females; in contrast, autonomic symptoms were more profound in females[18,19].

Concomitant autoimmune diseases such as, Sicca Syndrome, Scleroderma and Raynaud’s phenomenon, were shown to be less prevalent in men. These findings suggest that females are more likely to suffer concomitant autoimmune disease than males. The complications of hepatocellular carcinoma (HCC) in patients with PBC were reported to be significantly greater in men than in women[20]. Biochemical levels of alkaline phosphatase (ALP), alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase (gGT) were reported to be slightly higher in symptomatic males compared to asymptomatic males, but both were higher than in females[21]. The only histologicaldifference identified were that symptomatic female patients had more piecemeal necrosis of the liver and that symptomatic males had more stainable copper storage than asymptomatic males. Additionally, symptomatic females were reported to have more pseudoxanthomatous transformation than asymptomatic females[17]. AIH is a liver disease characterized by progressive inflammatory destruction of the parenchyma. AIH is associated with the presence of circulating autoantibodies, hypergammaglobulinemia and interface hepatitis on liver biopsy. AIH typically responds to immunosuppressive therapy[22].

The etiology of AIH is unknown, though both genetic and environmental factors are involved. It has been suggested that the major mechanism of liver damage is the failure of impaired regulatory T cells to control immune reactions against liver host antigens.

The actual prevalence of AIH is unknown. AIH is characterized by a strong female preponderance (the female/male ratio is 3.6/1)[23]. There are no sex or gender differences in age, form of clinical onset, frequency of symptomatic concurrent autoimmune diseases, and human leukocyte antigen DR (HLA DR) status. Several studies have demonstrated that in men, there is a minor frequency of normalization of ALT stages after 6 mo of corticosteroid treatment[24]. However, men with AIH appeared to have better long-term survival and outcome than women[25]. In females the severity of AIH was found to be likely to decrease during the second trimester of pregnancy, when estrogen was secreted at high levels and acute AIH exacerbation occurred occur after delivery[26]. High levels of estrogen are associated with an anti inflammatory milieu[27]. Moreover females have a higher frequency of concurrent immunological disorders such as Sicca Syndrome at presentation than males.

Al-Chalabi *et al*[25]discovered the extended haplotype HLA A1–B8–DR3 (associated withincreased susceptibility to AIH) was more than twice as prevalent in male patients as in female patients with AIH.

Primary Sclerosing Cholangitis (PSC) is a chronic cholestatic liver disease characterized by progressive inflammation and fibrosis of the intrahepatic andextrahepatic bile ducts. PSC leads to cholestasis, progressive hepatic fibrosis and eventually decompensated cirrhosis[28,29].

The incidence of PSC is 1:100000 people. Previous studies have demonstrated that PSC is more prevalent in men than in women (M > F 7:3). In the United States, between 62% and 70% of patients are male[30]. The pathogenesis of PSC is unclear because it is a complex immune-mediated disease. The most accepted theory is that in genetically predisposed individuals, the environmental exposure to infective agents or toxins causes persistent immunemediated damage to cholangiocytes and progressive destruction of bile ducts, which leads to chronic cholestasis[31] (Table 1).

**Alcoholic Liver Disease**

Alcohol abuse and its various complications are still widespread in the Western World and represent a frequent cause of hepatic damage. The excessive consumption of alcohol may cause hepatic steatosis, alcoholic hepatitis and cirrhosis. Alcoholic cirrhosis causes approximately 40% of deaths due to cirrhosis. The severe forms (hepatitis, cirrhosis) are associated with ingestion of 160 g/die of alcohol in 10-20 years. The incidence of alcoholic liver disease increases proportionally with the consumption of alcohol. Several surveys have demonstrated that hepatic damage develops faster in women than in men. In cases of heavy drinkers with a weekly consumption of 336-492 g, the relative risk of developing cirrhosis was equivalent to 7 in men and 17 in women. Furthermore, the relative risk of developing alcoholic liver disease was 3.7 in men and 7.3 in women. The factors regulating in the differences in susceptibility to alcoholic toxicity include the following: age during alcohol consumption, the manner of alcohol consumption (with or without meals) and the nutritional state of the individual[32].

Women are more susceptible to damage by alcohol compared to men, which leads to more advanced liver disease after alcohol consumption. It has been demonstrated that, under the same conditions and assuming equal doses of alcohol, women reach higher blood ethanol concentrations than men. Moreover, it has been shown that females have a major risk of hepatitis progression toward cirrhosis after abstaining from alcohol[33,34]. The causes attributed to these gender differences include differences in corporal structures, different enzymatic activity and hormonal differences.

The process of metabolizing a substance before it enter the general circulation is called first-pass metabolism. Various studies have demonstrated that an isoform of gastric alcohol dehydrogenase (ADH) has a main role in alcohol metabolism. ADH activity is linked to the first passage of alcoholic metabolism and affects the blood ethanol concentration. At the gastric level, this enzyme is expressed less in women than in men. Furthermore, in a female heavy drinker the activity of gastric ADH is practically absent. Therefore in women a majority of alcohol reaches the liver directly, which may worsen the hepatic damages. Moreover, this situation contributes to the gender differences in blood concentration and contributes to unfavorable consequences of alcohol use[35]. Another cause of female vulnerability to the toxic effects of alcohol is the reduced content of corporal water compared to men[36].

The quantity of absorbed alcohol in the gastro-intestinal system that is not metabolized by first-pass metabolism enters the circulation. Hepatic ADH, in the liver is principally involved in alcohol metabolism. The amount of alcohol distributed in water determines the blood alcohol concentration. A woman has proportionally more fat and less water than a man. Thus, when the ethanol is distributed in water, the distribution volume in women is less, and the blood alcohol concentration is higher[35,37] (Table 2).

**NAFLD**

NAFLD is the most common chronic liver disease in the Western World, affecting 30% of the general adult population[38].

NAFLD is an umbrella term for a group of diseases defined by a hepatic fat infiltration in > 5% of hepatocytes, in the absence of excessive alcohol intake. Excessive alcohol intake is defined as two standard drinks (20 g ethanol) daily for men and one standard drink (10 g ethanol) daily for women. NAFLD encompasses a histological spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). NASH is defined by steatosis, hepatocellular damage and lobular inflammation[39] in individuals without significant alcohol consumption and without viral, congenital and autoimmune liver disease markers.

There have been parallel increases in the prevalence rates of obesity, metabolic syndrome (hyperglycemia, visceral obesity, hyperlipidemia and hypertension) and NASH. As a result, NASH is considered part of metabolic syndrome (MS)[40].

MS is a risk factor for cardiovascular disease, its high prevalence has substantially affected public health in recent years[41]. There are varied reports in the literature regarding the gender distribution of MS. Several studies report a higher incidence of MS in men than in women, but the reverse has been shown in other reports[42].

The prevalence of MS increases with the general population age and is more likely in black and Hispanic female populations. The accumulation of hepatic and intra-abdominal fat is not different between genders, but it is affected by dietary lipid consumption[43]. Abdominal fat tissue is a major source of free fatty acids and cytokines for the liver, and fat favors the early development of insulin resistance, dyslipidemia, and high blood pressure. The more favorable fat distribution in women demonstrates why women need a higher degree of adiposity to achieve the same metabolic disturbances as men[44]. Subcutaneous and visceral adipose tissue types are influenced by age and gender. Visceral adipose tissue accumulates more rapidly with age and weight gain in males and postmenopausal females than in younger females[45]. The difference in the prevalence of MS between genders has been attributed to sex hormones. Many studies have shown that, in postmenopausal women, the distribution of their body fat changes toward visceral adiposity[46].There are differing reports in the literature concerning the association between gender and NASH. In some studies, NAFLD was approximately 1.5 times more prevalent in females than in males whereas other studies did not find any differences, between genders[47,48].Some studies have shown that female gender is a risk factor for NASH[49], but the current literature presents conflicting results[50,51]. A population, based study suggested that endogenous estrogens have a protective role in NASH, which may explain why the prevalence of NAFLD increases in women over 50 years of age[52].

In conclusion, although the sex differences for fibrosis in patients with NAFLD are not identical, women tend develop more, severe fibrosis than men[53].

The possible roles of estrogen in hepatic lipid metabolism and fibrosis require further investigation (Table 3).

**Chronic Hepatitis B**

Protracted treatment with nucleoside/nucleotide analogs has allowed for an improvement in the natural history of patients with chronic hepatitis B virus (HBV) infection by reducing the incidence of cirrhosis and the risk of complications[54].

Over the last 20 years, the epidemiology of HBV infection has radically changed in Italy. At the beginning of the 1980, the rate of HBV surface antigen (HBsAg) carriers in the general population was 3.5%, with peaks of 10% in Southern Italy. The current prevalence of carriers is less than 1%, and a majority of carriers are male. The rate of chronic infection is higher in men due to various factors and is widely studied. However, it is unclear if men are exposed to more viruses, or if men have a less effective immune response in eliminating. The major response in females is caused by the position of genes that determine the response, and most genes are located on the X chromosome. This hypothesis is supported by the female prevalence of two hepatic autoimmune diseases (PBC and AIH)[55]**.**

HBV does not meaningfully influence fertility, and contracting an HBV infection during a pregnancy does not increase morbidity or maternal or fetal mortality[56]. Recent evidences demonstrated that the increased production of proinflammatory cytokines in chronic hepatitis B (CHB)[57,58] may participate in the development of complications, such as gestational diabetes, pre-delivery hemorrhages and pre-term delivery[59]. Furthermore, in women with cirrhosis, there are higher frequencies of gestational hypertension, detachment of the placenta and peripartum hemorrhages compared with healthy controls[60].

A normal pregnancy with elevated levels of corticosteroid hormones and estrogens cause increased HBV viremia[61] and indices of cytolysis (ALT)[62]. Moreover, there have been reported cases of peripartum hepatitis with hepatic decompensation[63].

The main cause of fetal HBV transmission is delivery. The administration of immunoglobulins and an anti-HBV vaccine may prevent fetal infection in more than 85% of children born from HbsAg+ mothers[64].

Other minor causes of fetal and maternal transmission are intrauterine transmission (HBV may reach the foetus through the placental barrier)[65] and transmission during breastfeeding through virus ingestion or by contact with maternal cutaneous lesions[66].

There is currently no clear therapeutic way to prevent viral transmission. The pre-delivery administration of immunoglobulins has yelded discordant results[67,68]. The study by Beasley demonstrated that the administration of immunoglobulins and anti-HBV vaccine within 12 h of birth reduced the frequency of HBV transmission from > 90% to 26%[69,70].

A 2012 Chinese study evaluated the safety of Lamivudine treatment for CHB in early pregnancy. This study examined 92 chronic HBV-infected pregnant women who received Lamivudine treatment either before pregnancy or in early pregnancy. These women were not co-infected with hepatitis C virus, human immunodeficiency virus, cytomegalovirus, or other viruses. Adverse events were observed throughout the entire pregnancy and perinatal period. The effectiveness of Lamivudine treatment for blocking mother-to-infant transmission of HBV was evaluated. The data showed that treatment does not increase complications or adverse events for mothers during pregnancy or the perinatal period. Additionaly no effect on fertilization or embryonic development was found, and treatment did not increase the incidence of congenital abnormalities in infants. Furthermore, treatment reduced the rate of mother-to-infant transmission[71]*.* A case report described a treatment with triple therapy of Lamivudine, interferon (IFN)-beta and prednisolone for acute CHB exacerbation during pregnancy. The patient’s liver enzymes became elevated toward the end of the first trimester. She was treated with Lamivudine, interferon-beta and steroids early in the second trimester. After this treatment, aminotransferase levels rapidly normalized within 4 wk. Lamivudine was continued until delivery. Spontaneous delivery occurred at 37 wk of gestation. There were not congenital anomalies, and fetal growth was found to be within normal reference ranges. This case report suggests that combination therapy with Lamivudine, IFN-beta and steroids may be safely used during the pregnancy to treat acute CHB exacerbations[72].

There are ongoing studies investigating the use of antiviral medicines in mothers with high HBV DNA levels. Currently the oral antivirals Telbivudine and Tenofovir are classified as “FDA pregnancy category B”, whereas the other antiviral drugs are classified as “FDA pregnancy category C”. A recent meta-analysis has demonstrated that Telbivudine use in the final stage of pregnancy is effective in preventing or reducing the perinatal transmission of HBV without meaningful or unfavorable effects[73].

Some data exist on Tenofovir in HIV positive women but these data show increased congenital malformations, kidney damage and distorted bone metabolism after exposure in utero[74] (Table 4).

**Chronic Hepatitis C**

Hepatitis C virus (HCV) infection affects 130-170 million people worldwide, which is approximately 2%-3% of the global population. HCV is transmitted by parenteral routes, such as contact with infected blood or contaminated materials and intravenous drugs injection with contaminated syringes. Although less common, HCV can be transmitted by sexual contact with HCV-positive partners[75,76]. Several studies have demonstrated that women have less altered hepatic biochemical tests and lower rates of fibrosis progression[77]. These findings are related to the protective effects of estrogens, which possess anti-fibrotic properties. Estrogens have a role in blocking fibrogenesis in hepatic stellate cells. The notion that estrogen has a protective role was also suggested by evidence that menopause is associated with an accelerated rate of fibrotic progression and that hormone replacement therapy may minimize this effect[78]. The prevalence of HCV infection in pregnancy is 1%-2% in the United States and Europe. However, the rate of HCV, may reach up to 8% in some developing countries[79].

The documented mother-to-child transmission (MTCT) frequency of HCV is approximately 5%-10%[80]. The pathogenesis of HCV infection during pregnancy and the neonatal period is unclear. During pregnancy, the maternal immune system has to develop tolerance to paternal antigenes to avoid any maternal immune assault towards the fetus. Simultaneously, the maternal immune system most maintain active immunity against HCV to protect both the mother and fetus from infection. This modulation of immune responses is different during each stage of pregnancy[81]. In developed countries, vertical transmission is the main cause of pediatric-HCV infection. The factors demonstrated to increase the risk of maternal-fetal transmission include amniocentesis, the extended breaking of the membranes and an elevated viral load in the mother. Perinatal HCV transmission is confined to women with HCV RNA present in their peripheral blood; it occurs rarely if the maternal viral load less than 1 × 105 HCV RNA copies / ml of plasma[82].

Two previous studies demonstrated that high levels of ALT in the year before pregnancy are linked with a higher maternal-fetal transmission rate. These results suggest that the development of liver damage in the mother is a potential risk factor for HCV transmission[83]. Furthermore, HCV infection and signs of viral replications in maternal peripheral blood mononuclear cells enhances the rate of transmission[84]. Conversely, breastfeeding and genotype do not appear to be linked to MTCT. A co-infection with HIV virus increases the likelihood of vertical HCV transmission by 90%[85].

The standard treatment for chronic HCV infection is PEG-IFNα and ribavirin. Recently, the new antiviral medicines, telaprevir and boceprevir were introduced[86].

Little is known about the real impact of gender on the characteristics that influence the efficacy and safety of chronic hepatitis C treatment. Several studies have demonstrated that the sustained virological response (SVR) rate is significantly higher in women than in men, and fertile women with normal genotypes have a 100% chance of obtaining a SVR. Therefore the administration of combined therapy is not recommended during pregnancy (Pregnancy FDA Category X)[87] (Table 5).

**Genetic Hemochromatosis**

Iron is essential for many biological processes. The liver stores for iron and plays a central role in the regulation of iron metabolism. The liver synthesizes hepcidin, which is the most important iron regulatory hormone.

Genetic hemochromatosis (GH) is a prevalent iron overload disorder in the Caucasian population. Patients absorb more than the normal amount of iron through the intestine. Hepcidin is suggested to play a role in GH.

GH is not a gender-specific disease, but more males than females present symptoms and signs of hemochromatosis. Men accumulate more iron and have a higher incidence of liver injury[88].

The clinical symptoms of GH usually begin later in women than in men, likely due to the physiological loss of blood in women of childbearing age. The gender-specific regulation of hepcidin synthesis in the liver may play a role in this process[89].

The prevalence of the disease in men may also be explained by the greater extrahepatic deposition of iron in males than in females. In addition, serum ferritin levels are higher in men, which suggests that men have increased extrahepatic iron stores[90].

In conclusion, the clinical presentation of GH is different between women and men. Both liver disease and diabetes are more common in men, whereas fatigue and pigmentation are more common in women[91].

**Conclusion**

Gender medicine focuses the scientific community on understanding and analyzing clinical, patho-physiological, prevention and treatment differences in diseases that are equally represented in men and women[1].

Current medicine offers better care through the study of disease mechanisms based on gender differences by focusing on the incidence and etiology of pathologies, clinical objectives and the response to therapies[33]. The purpose of this fields is to provide the best treatment possible to each individual man and woman based on scientific evidences.

This review emphasized the importance of appropriate management of viral chronic hepatitis during pregnancy and summarized the strategies to prevent mother-to-child transmission. The review focused on maternal and perinatal outcomes, disease progression and its impact on pregnancy, and the new effectivedrugs used to prevent maternal infection transmission without significant adverse effects or complications. In summary, based on the current literature, we recommend close maternal-fetal monitoring during pregnancy and suggest that all available treatment options be considered in the future.

**References**

|  |
| --- |
| 1 **Baggio G**, Corsini A, Floreani A, Giannini S, Zagonel V. Gender medicine: a task for the third millennium. *Clin Chem Lab Med* 2013; **51**: 713-727 [PMID: 23515103 DOI: 10.1515/cclm-2012-0849]2 **Floreani A**, Cazzagon N, Boemo DG, Baldovin T, Baldo V, Egoue J, Antoniazzi S, Minola E. Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response. *Eur J Gastroenterol Hepatol* 2011; **23**: 997-1003 [PMID: 21915057 DOI: 10.1097/MEG.0b013e32834ae863]3 **Amadori A**, Zamarchi R, De Silvestro G, Forza G, Cavatton G, Danieli GA, Clementi M, Chieco-Bianchi L. Genetic control of the CD4/CD8 T-cell ratio in humans. *Nat Med* 1995; **1**: 1279-1283 [PMID: 7489409 DOI: 10.1038/nm1295-1279]4 **Gilmore W**, Weiner LP, Correale J. Effect of estradiol on cytokine secretion by proteolipid protein-specific T cell clones isolated from multiple sclerosis patients and normal control subjects. *J Immunol* 1997; **158**: 446-451 [PMID: 8977221]5 **Araneo BA**, Dowell T, Diegel M, Daynes RA. Dihydrotestosterone exerts a depressive influence on the production of interleukin-4 (IL-4), IL-5, and gamma-interferon, but not IL-2 by activated murine T cells. *Blood* 1991; **78**: 688-699 [PMID: 1830499]6 **Kaplan MM**, Gershwin ME. Primary biliary cirrhosis. *N Engl J Med* 2005; **353**: 1261-1273 [PMID: 16177252 DOI: 10.1056/NEJMra043898]7 **Hohenester S**, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. *Semin Immunopathol* 2009; **31**: 283-307 [PMID: 19603170 DOI: 10.1007/s00281-009-0164-5]8 **Neuberger J**. Primary biliary cirrhosis. *Lancet* 1997; **350**: 875-879 [PMID: 9310614 DOI: 10.1016/S0140-6736(97)05419-6]9 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 2002: 241-25310 **Nalbandian G**, Van de Water J, Gish R, Manns M, Coppel RL, Rudich SM, Prindiville T, Gershwin ME. Is there a serological difference between men and women with primary biliary cirrhosis? *Am J Gastroenterol* 1999; **94**: 2482-2486 [PMID: 10484012]11 **Kim WR**, Lindor KD, Locke GR, Therneau TM, Homburger HA, Batts KP, Yawn BP, Petz JL, Melton LJ, Dickson ER. Epidemiology and natural history of primary biliary cirrhosis in a US community. *Gastroenterology* 2000; **119**: 1631-1636 [PMID: 11113084 DOI: 10.1053/gast.2000.20197]12 **Selmi C**, Brunetta E, Raimondo MG, Meroni PL. The X chromosome and the sex ratio of autoimmunity. *Autoimmun Rev* 2012; **11**: A531-A537 [PMID: 22155196 DOI: 10.1016/j.autrev.2011.11.024]13 **Invernizzi P**, Miozzo M, Battezzati PM, Bianchi I, Grati FR, Simoni G, Selmi C, Watnik M, Gershwin ME, Podda M. Frequency of monosomy X in women with primary biliary cirrhosis. *Lancet* 2004; **363**: 533-535 [PMID: 14975617 DOI: 10.1016/S0140-6736(04)15541-4]14 **Invernizzi P**, Miozzo M, Selmi C, Persani L, Battezzati PM, Zuin M, Lucchi S, Meroni PL, Marasini B, Zeni S, Watnik M, Grati FR, Simoni G, Gershwin ME, Podda M. X chromosome monosomy: a common mechanism for autoimmune diseases. *J Immunol* 2005; **175**: 575-578 [PMID: 15972694]15 **Selmi C**, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish RG, Gordon SC, Wright HI, Zweiban B, Podda M, Gershwin ME. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. *Gastroenterology* 2004; **127**: 485-492 [PMID: 15300581 DOI: 10.1053/j.gastro.2004.05.005]16 **Lleo A**, Oertelt-Prigione S, Bianchi I, Caliari L, Finelli P, Miozzo M, Lazzari R, Floreani A, Donato F, Colombo M, Gershwin ME, Podda M, Invernizzi P. Y chromosome loss in male patients with primary biliary cirrhosis. *J Autoimmun* 2013; **41**: 87-91 [PMID: 23375847 DOI: 10.1016/j.jaut.2012.12.008]17 **Rubel LR**, Rabin L, Seeff LB, Licht H, Cuccherini BA. Does primary biliary cirrhosis in men differ from primary biliary cirrhosis in women? *Hepatology* ; **4**: 671-677 [PMID: 6745856 DOI: 10.1002/hep.1840040418]18 **Newton JL**, Gibson GJ, Tomlinson M, Wilton K, Jones D. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. *Hepatology* 2006; **44**: 91-98 [PMID: 16800007 DOI: 10.1002/hep.21230]19 **Newton JL**, Hudson M, Tachtatzis P, Sutcliffe K, Pairman J, Burt JA, Jones DE. Population prevalence and symptom associations of autonomic dysfunction in primary biliary cirrhosis. *Hepatology* 2007; **45**: 1496-1505 [PMID: 17538969 DOI: 10.1002/hep.21609]20 **Lucey MR**, Neuberger JM, Williams R. Primary biliary cirrhosis in men. *Gut* 1986; **27**: 1373-1376 [PMID: 3792920 DOI: 10.1136/gut.27.11.1373]21 **Muratori P**, Granito A, Pappas G, Muratori L, Quarneti C, De Molo C, Cipriano V, Vukotic R, Andreone P, Lenzi M, Bianchi FB. Clinical and serological profile of primary biliary cirrhosis in men. *QJM* 2007; **100**: 534-535 [PMID: 17609225 DOI: 10.1093/qjmed/hcm059]22 **Alvarez F**, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Büschenfelde KH, Zeniya M. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. *J Hepatol* 1999; **31**: 929-938 [PMID: 10580593 DOI: 10.1016/S0168-8278(99)80297-9]23 **Manns MP**, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. *Hepatology* 2010; **51**: 2193-2213 [PMID: 20513004 DOI: 10.1002/hep.23584]24 **Miyake Y**, Iwasaki Y, Sakaguchi K, Shiratori Y. Clinical features of Japanese male patients with type 1 autoimmune hepatitis. *Aliment Pharmacol Ther* 2006; **24**: 519-523 [PMID: 16886918 DOI: 10.1111/j.1365-2036.2006.03013.x]25 **Al-Chalabi T**, Underhill JA, Portmann BC, McFarlane IG, Heneghan MA. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. *J Hepatol* 2008; **48**: 140-147 [PMID: 18023911 DOI: 10.1016/j.jhep.2007.08.013]26 **Buchel E**, Van Steenbergen W, Nevens F, Fevery J. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. *Am J Gastroenterol* 2002; **97**: 3160-3165 [PMID: 12492204 DOI: 10.1111/j.1572-0241.2002.07124.x]27 **Whitacre CC**. Sex differences in autoimmune disease. *Nat Immunol* 2001; **2**: 777-780 [PMID: 11526384 DOI: 10.1038/ni0901-777]28 **Wiesner RH**, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, Fleming TR, Fisher LD, Beaver SJ, LaRusso NF. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. *Hepatology* 1989; **10**: 430-436 [PMID: 2777204 DOI: 10.1002/hep.1840100406]29 **Bambha K**, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, Loftus EV, Yawn BP, Dickson ER, Melton LJ. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. *Gastroenterology* 2003; **125**: 1364-1369 [PMID: 14598252 DOI: 10.1016/j.gastro.2003.07.011]30 **Molodecky NA**, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, Kaplan GG. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. *Hepatology* 2011; **53**: 1590-1599 [PMID: 21351115 DOI: 10.1002/hep.24247]31 **Pollheimer MJ**, Halilbasic E, Fickert P, Trauner M. Pathogenesis of primary sclerosing cholangitis. *Best Pract Res Clin Gastroenterol* 2011; **25**: 727-739 [PMID: 22117638 DOI: 10.1016/j.bpg.2011.10.009]32 **Nagoshi S**. Sex- or gender-specific medicine in hepatology. *Hepatol Res* 2008; **38**: 219-224 [PMID: 18047583 DOI: 10.1111/j.1872-034X.2007.00301.x]33 **Lelbach WK**. Quantitative aspects of drinking in alcoholic liver cirrhosis. In: Khanna JM, Israel Y, Kalant H eds. Alcoholic liver pathology. Alcoholism and drug addiction research foundation of Ontario, Canada. Toronto: Blackwell Publishing, 197534 **Lelbach WK**. Cirrhosis in the alcoholic and its relation to the volume of alcohol abuse. *Ann N Y Acad Sci* 1975; **252**: 85-105 [PMID: 1096716 DOI: 10.1111/j.1749-6632.1975.tb19146.x]35 **Frezza M**, di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. *N Engl J Med* 1990; **322**: 95-99 [PMID: 2248624 DOI: 10.1056/NEJM199001113220205]36 **Mancinelli R**, Guiducci MS. [Women and alchol: biological vulnerability]. *Ann Ist Super Sanita* 2004; **40**: 19-23 [PMID: 15269448]37 **Thomasson HR**. Gender differences in alcohol metabolism. Physiological responses to ethanol. *Recent Dev Alcohol* 1995; **12**: 163-179 [PMID: 7624539]38 **Musso G**, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. *Obes Rev* 2010; **11**: 430-445 [PMID: 19845871 DOI: 10.1111/j.1467-789X.2009.00657.x]39 **Farrell GC**, Hall P, George J, McCullough AJ, eds. Fatty Liver Disease: NASH and Related Disorders. Blackwell: Malden, MA, 2005: 181–19340 **Nonomura A**, Mizukami Y, Unoura M, Kobayashi K, Takeda Y, Takeda R. Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis. *Gastroenterol Jpn* 1992; **27**: 521-528 [PMID: 1526433]41 **Kahn R**, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2005; **28**: 2289-2304 [PMID: 16123508 DOI: 10.2337/diacare.28.9.2289]42 **He Y**, Jiang B, Wang J, Feng K, Chang Q, Fan L, Li X, Hu FB. Prevalence of the metabolic syndrome and its relation to cardiovascular disease in an elderly Chinese population. *J Am Coll Cardiol* 2006; **47**: 1588-1594 [PMID: 16630995 DOI: 10.1016/j.jacc.2005.11.074]43 **Floreani A**, Variola A, Niro G, Premoli A, Baldo V, Gambino R, Musso G, Cassader M, Bo S, Ferrara F, Caroli D, Rizzotto ER, Durazzo M. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. *Am J Gastroenterol* 2008; **103**: 1959-1965 [PMID: 18564121 DOI: 10.1111/j.1572-0241.2008.01888.x]44 **Regitz-Zagrosek V**, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. *Clin Res Cardiol* 2006; **95**: 136-147 [PMID: 16598526 DOI: 10.1007/s00392-006-0351-5]45 **Shen W**, Punyanitya M, Silva AM, Chen J, Gallagher D, Sardinha LB, Allison DB, Heymsfield SB. Sexual dimorphism of adipose tissue distribution across the lifespan: a cross-sectional whole-body magnetic resonance imaging study. *Nutr Metab* (Lond) 2009; **6**: 17 [PMID: 19371437 DOI: 10.1186/1743-7075-6-17]46 **Kotani K**, Tokunaga K, Fujioka S, Kobatake T, Keno Y, Yoshida S, Shimomura I, Tarui S, Matsuzawa Y. Sexual dimorphism of age-related changes in whole-body fat distribution in the obese. *Int J Obes Relat Metab Disord* 1994; **18**: 207-202 [PMID: 8044194]47 **Hamaguchi M**, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. *Ann Intern Med* 2005; **143**: 722-728 [PMID: 16287793 DOI: 10.7326/0003-4819-143-10-200511150-00009]48 **Adams LA**, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. *Am J Gastroenterol* 2009; **104**: 861-867 [PMID: 19293782 DOI: 10.1038/ajg.2009.67]49 **Farrell GC**, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. *Hepatology* 2006; **43**: S99-S112 [PMID: 16447287 DOI: 10.1002/hep.20973]50 **Ratziu V**, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. *Gastroenterology* 2000; **118**: 1117-1123 [PMID: 10833486 DOI: 10.1016/S0016-5085(00)70364-7]51 **Daryani NE**, Daryani NE, Alavian SM, Zare A, Fereshtehnejad SM, Keramati MR, Pashaei MR, Habibollahi P. Non-alcoholic steatohepatitis and influence of age and gender on histopathologic findings. *World J Gastroenterol* 2010; **16**: 4169-4175 [PMID: 20806434 DOI: 10.3748/wjg.v16.i33.4169]52 **Völzke H**, Schwarz S, Baumeister SE, Wallaschofski H, Schwahn C, Grabe HJ, Kohlmann T, John U, Dören M. Menopausal status and hepatic steatosis in a general female population. *Gut* 2007; **56**: 594-595 [PMID: 17369390 DOI: 10.1136/gut.2006.115345]53 **Fan JG**, Saibara T, Chitturi S, Kim BI, Sung JJ, Chutaputti A. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? *J Gastroenterol Hepatol* 2007; **22**: 794-800 [PMID: 17498218 DOI: 10.1111/j.1440-1746.2007.04952.x]54 **Niro GA**, Ippolito AM, Fontana R, Valvano MR, Gioffreda D, Iacobellis A, Merla A, Durazzo M, Lotti G, Di Mauro L, Andriulli A. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues. *J Viral Hepat* 2013; **20**: 502-509 [PMID: 23730844 DOI: 10.1111/jvh.12054]55 **Invernizzi P**. Isegreti del cromosoma X. *Humanitas* 2009; **2**: 14-1556 **Tan J**, Surti B, Saab S. Pregnancy and cirrhosis. *Liver Transpl* 2008; **14**: 1081-1091 [PMID: 18668664 DOI: 10.1002/lt.21572]57 **Sheron N**, Lau J, Daniels H, Goka J, Eddleston A, Alexander GJ, Williams R. Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection. *J Hepatol* 1991; **12**: 241-245 [PMID: 2051003 DOI: 10.1016/0168-8278(91)90945-8]58 **Bozkaya H**, Bozdayi M, Türkyilmaz R, Sarioglu M, Cetinkaya H, Cinar K, Köse K, Yurdaydin C, Uzunalimoglu O. Circulating IL-2, IL-10 and TNF-alpha in chronic hepatitis B: their relations to HBeAg status and the activity of liver disease. *Hepatogastroenterology* 2000; **47**: 1675-1679 [PMID: 11149030]59 **Luppi P**, Haluszczak C, Trucco M, Deloia JA. Normal pregnancy is associated with peripheral leukocyte activation. *Am J Reprod Immunol* 2002; **47**: 72-81 [PMID: 11900591]60 **Shaheen AA**, Myers RP. The outcomes of pregnancy in patients with cirrhosis: a population-based study. *Liver Int* 2010; **30**: 275-283 [PMID: 19874491 DOI: 10.1111/j.1478-3231.2009.02153.x]61 **ter Borg MJ**, Leemans WF, de Man RA, Janssen HL. Exacerbation of chronic hepatitis B infection after delivery. *J Viral Hepat* 2008; **15**: 37-41 [PMID: 18088243]62 **Tan HH**, Lui HF, Chow WC. Chronic hepatitis B virus (HBV) infection in pregnancy. *Hepatol Int* 2008; **2**: 370-375 [PMID: 19669267 DOI: 10.1007/s12072-008-9063-4]63 **Nguyen G**, Garcia RT, Nguyen N, Trinh H, Keeffe EB, Nguyen MH. Clinical course of hepatitis B virus infection during pregnancy. *Aliment Pharmacol Ther* 2009; **29**: 755-764 [PMID: 19183158 DOI: 10.1111/j.1365-2036.2009.03932.x]64 **Kumar A**. Hepatitis B virus infection and pregnancy: a practical approach. *Indian J Gastroenterol* 2012; **31**: 43-54 [PMID: 22528342 DOI: 10.1007/s12664-012-0174-4]65 **Degli Esposti S**, Shah D. Hepatitis B in pregnancy: challenges and treatment. *Gastroenterol Clin North Am* 2011; **40**: 355-72, viii [PMID: 21601784 DOI: 10.1016/j.gtc.2011.03.005]66 **Wong VC**, Lee AK, Ip HM. Transmission of hepatitis B antigens from symptom free carrier mothers to the fetus and the infant. *Br J Obstet Gynaecol* 1980; **87**: 958-965 [PMID: 7437368 DOI: 10.1111/j.1471-0528.1980.tb04458.x]67 **Li XM**, Shi MF, Yang YB, Shi ZJ, Hou HY, Shen HM, Teng BQ. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. *World J Gastroenterol* 2004; **10**: 3215-3217 [PMID: 15457579]68 **Yuan J**, Lin J, Xu A, Li H, Hu B, Chen J, Yao J, Dong H, Jiang M. Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effective: a single-centre randomized study. *J Viral Hepat* 2006; **13**: 597-604 [PMID: 16907846 DOI: 10.1111/j.1365-2893.2006.00738.x]69 **Beasley RP**, Hwang LY, Lin CC, Stevens CE, Wang KY, Sun TS, Hsieh FJ, Szmuness W. Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial. *Lancet* 1981; **2**: 388-393 [PMID: 6115159 DOI: 10.1016/S0140-6736(81)90832-1]70 **Beasley RP**, Hwang LY, Stevens CE, Lin CC, Hsieh FJ, Wang KY, Sun TS, Szmuness W. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. *Hepatology* 1983; **3**: 135-141 [PMID: 6339349 DOI: 10.1002/hep.1840030201]71 **Yi W**, Liu M, Cai HD. Safety of lamivudine treatment for chronic hepatitis B in early pregnancy. *World J Gastroenterol* 2012; **18**: 6645-6650 [PMID: 23236240 DOI: 10.3748/wjg.v18.i45.6645.]72 **Koh M**, Shinohara J, Hongo Y, Okazaki T, Takitani K, Tamai H. Case treated with triple therapy of lamivudine, interferon-β and prednisolone for acute exacerbation of chronic hepatitis B during pregnancy. *Hepatol Res* 2013; **43**: 425-429 [PMID: 23560863 DOI: 10.1111/j.1872-034X.2012.01077.x]73 **Deng M**, Zhou X, Gao S, Yang SG, Wang B, Chen HZ, Ruan B. The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. *Virol J* 2012; **9**: 185 [PMID: 22947333 DOI: 10.1186/1743-422X-9-185]74 **Giles M**, Visvanathan K, Sasadeusz J. Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding. *Antivir Ther* 2011; **16**: 621-628 [PMID: 21817183 DOI: 10.3851/IMP1813]75 **Zahran KM**, Badary MS, Agban MN, Abdel Aziz NH. Pattern of hepatitis virus infection among pregnant women and their newborns at the Women's Health Center of Assiut University, Upper Egypt. *Int J Gynaecol Obstet* 2010; **111**: 171-174 [PMID: 20708181 DOI: 10.1016/j.ijgo.2010.06.013]76 **Lavanchy D**. The global burden of hepatitis C. *Liver Int* 2009; **29** Suppl 1: 74-81 [PMID: 19207969 DOI: 10.1111/j.1478-3231.2008.01934.x]77 **Narciso-Schiavon JL**, Schiavon LL, Carvalho-Filho RJ, Freire FC, Cardoso JR, Bordin JO, Silva AE, Ferraz ML. Anti-hepatitis C virus-positive blood donors: are women any different? *Transfus Med* 2008; **18**: 175-183 [PMID: 18598280 DOI: 10.1111/j.1365-3148.2008.00859.x]78 **Di Martino V**, Lebray P, Myers RP, Pannier E, Paradis V, Charlotte F, Moussalli J, Thabut D, Buffet C, Poynard T. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. *Hepatology* 2004; **40**: 1426-1433 [PMID: 15565616 DOI: 10.1002/hep.20463]79 **Arshad M**, El-Kamary SS, Jhaveri R. Hepatitis C virus infection during pregnancy and the newborn period--are they opportunities for treatment? *J Viral Hepat* 2011; **18**: 229-236 [PMID: 21392169 DOI: 10.1111/j.1365-2893.2010.01413.x]80 **Klevens RM**, Hu DJ, Jiles R, Holmberg SD. Evolving epidemiology of hepatitis C virus in the United States. *Clin Infect Dis* 2012; **55** Suppl 1: S3-S9 [PMID: 22715211 DOI: 10.1093/cid/cis393]81 **Conte D**, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. *Hepatology* 2000; **31**: 751-755 [PMID: 10706568 DOI: 10.1002/hep.510310328]82 **Pergam SA**, Wang CC, Gardella CM, Sandison TG, Phipps WT, Hawes SE. Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort. *Am J Obstet Gynecol* 2008; **199**: 38.e1-38.e9 [PMID: 18486089]83 **Hayashida A**, Inaba N, Oshima K, Nishikawa M, Shoda A, Hayashida S, Negishi M, Inaba F, Inaba M, Fukasawa I, Watanabe H, Takamizawa H. Re-evaluation of the true rate of hepatitis C virus mother-to-child transmission and its novel risk factors based on our two prospective studies. *J Obstet Gynaecol Res* 2007; **33**: 417-422 [PMID: 17688606 DOI: 10.1111/j.1447-0756.2007.00582.x]84 **Azzari C**, Moriondo M, Indolfi G, Betti L, Gambineri E, de Martino M, Resti M. Higher risk of hepatitis C virus perinatal transmission from drug user mothers is mediated by peripheral blood mononuclear cell infection. *J Med Virol* 2008; **80**: 65-71 [PMID: 18041020 DOI: 10.1002/jmv.21023]85 **Polis CB**, Shah SN, Johnson KE, Gupta A. Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: a meta-analysis. *Clin Infect Dis* 2007; **44**: 1123-1131 [PMID: 17366462 DOI: 10.1086/512815]86 **McHutchison JG**, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM. Telaprevir for previously treated chronic HCV infection. *N Engl J Med* 2010; **362**: 1292-1303 [PMID: 20375406 DOI: 10.1056/NEJMoa0908014]87 **Roberts SS**, Miller RK, Jones JK, Lindsay KL, Greene MF, Maddrey WC, Williams IT, Liu J, Spiegel RJ. The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009. *Birth Defects Res A Clin Mol Teratol* 2010; **88**: 551-559 [PMID: 20564430 DOI: 10.1002/bdra.20682]88 **Fleming RE**, Britton RS, Waheed A, Sly WS, Bacon BR. Pathogenesis of hereditary hemochromatosis. *Clin Liver Dis* 2004; **8**: 755-73, vii [PMID: 15464654 DOI: 10.1016/j.cld.2004.06.004]89 **Eijkelkamp EJ**, Yapp TR, Powell LW. HFE-associated hereditary hemochromatosis. *Can J Gastroenterol* 2000; **14**: 121-125 [PMID: 10694284]90 **Moirand R**, Adams PC, Bicheler V, Brissot P, Deugnier Y. Clinical features of genetic hemochromatosis in women compared with men. *Ann Intern Med* 1997; **127**: 105-110 [PMID: 9229998 DOI: 10.7326/0003-4819-127-2-199707150-00002]91 **Adams PC**, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. *Hepatology* 1997; **25**: 162-166 [PMID: 8985284 DOI: 10.1002/hep.510250130] |

**P-Reviewer:** Carvalho RJ, Chwist A, Larentzakis A **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Table 1 Gender differences in primary biliary cirrhosis and autoimmune hepatitis**

|  |  |
| --- | --- |
| **Primary biliary cirrhosis** | **Autoimmune hepatitis** |
|  |  |
| M/F ratio 1:10 | M/F ratio 1:3.6 |
|  |  |
| Age at diagnosis higher in M than in F (62 *vs* 51 yr) | Normalization of ALT levels after 6 mo of |
|  | corticosteroid treatment less frequent in M than in F |
|  |  |
| M less symptomatic than F: pruritus, abdominal | Better long-term survival and outcome |
| pain/discomfort and constitutional symptoms | in M than F |
| more common in F; jaundice and upper |  |
| gastrointestinal bleeding more common in M |  |
|  |  |
| Concomitant autoimmune diseases more common | Decrease of severity during second trimester of |
| in F (Sicca syndrome, sclerodermia, raynaud | pregnancy and possible onset of acute |
| phenomenon), whereas HCC complication are | exacerbationafter delivery |
| Significantly greater in M |  |
|  |  |
| ALP, ALT and gGT higher in M than F | Haplotype HLA A1-B8-DR3 more |
|  | prevalent in M than in F |
|  |  |
| Piecemealnecrosis and pseudoxanthomatous | Higher frequency of concurrent immunological |
| trasformation greater in symptomatic F | disorders at presentation in F than M |
|  |  |

HCC: hepatocellular carcinoma; ALP: alkaline phosphatase; ALT: alanine aminotransferase; gGT: gamma-glutamyl transpeptidase; HLA: human leukocyte antigen; F: female; M: male.

**Table 2 Gender differences in alcoholic liver disease**

|  |
| --- |
| **Alcoholic liver disease** **(hepatic steatosis - alcoholic hepatitis - cirrhosis)** |
| Hepatic damage faster in F than M |
| RR to develop cirrhosis 7 in M and 17 in F |
| RR to develop alcoholic liver disease 3, 7 in M and 7, 3 in F |
| F more susceptible to damage by alcohol than M: -higher haematic concentration of ethanol in F than M -major risk of hepatitis progression toward cirrohosis (even after an absentation from alcohol) in F than M |
| Differences in corporal structures (content of corporal water), different enzymatic activity (gastric ADH expression and activity), hormonal |

ADH: alcohol dehydrogenase; RR: relative risk; F: female; M: male.

**Table 3 non alcoholic fatty liver disease and gender**

|  |
| --- |
| **NAFLD and gender** |
| Prevalence of MS in men and postmenopausal womenPrevalence of visceral adiposity in men and postmenopausal woman |
| Possible link to MS, NAFLD and sex hormones |

NAFLD: non alcoholic fatty liver disease; MS: metabolic syndrome.

**Table 4 Chronic hepatitis B during the pregnancy and in the foetus**

|  |  |
| --- | --- |
| **HBV and pregnancy** | **HBV and foetus** |
|  |  |
| Not increases in maternal morbidity and | Maternal transmission: during delivery, |
| mortality | intrauterine transmission and during |
|  | Breastfeeding |
|  |  |
| Increases HBV viremia levels and indices of | Discordant results from pre-delivery |
| cytolysis | administration of Ig and anti-HBV vaccine |
|  |  |
| Development of complications (gestational | Administration of Ig and anti-HBV vaccine |
| diabetes, pre-delivery hemorrhages and | during delivery to prevent infection |
| pre-term delivery) |  |
|  |  |
| Higher frequency of gestational hypertension, | Ongoing studies about the use of antiviral medicines |
| detachment of placenta and peripartum | in F with high HBV DNA levels to prevent |
| hemorrhages in F with cirrhosis | perinataltransmission (Telbivudine and |
| Cases of peripartum hepatitis with hepatic | Tenofovir in FDA pregnancy category B) |
| Decompensation |  |
|  |  |

HBV: hepatitis B virus; F: Female.

**Table 5 Chronic hepatitis C during the pregnancy**

|  |
| --- |
| **Chronic hepatis C and pregnancy** |
| Frequency of HCV MTCT is 5%-10% |
| Vertical transmission is the main cause of pediatric HCV infection |
| Factors increasing the risk of MTCT: amniocentesis, extended breaking of the membranes and elevated viral load in the mother |
| High levels of ALT in the previous year of pregnancy are linked with a higher MTCT rate |
| Signs of viral replications is maternal peripheral blood mononuclear cells enhance vertical transmission |
| Breastfeeding and genotype are not linked to MTCT |
| Presence of HCV-HIV coinfection increases MTCT by 90% |
| The administration of combined therapy is not recommended during pregnancy |

HCV: Hepatitis C virus; HIV: human immunodeficiency virus; MTCT: mother-to-child transmission.